Clearmind Medicine Inc. announced the recruitment of the first patient at Tel Aviv Sourasky Medical Center for their Phase I/IIa clinical trial of CMND-100 in Alcohol Use Disorder. This marks the full activation of the prestigious Israeli site, joining other world-class centers in the study. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of CMND-100, a non-hallucinogenic compound. Recent results showed excellent safety and adherence. Clearmind is focused on developing psychedelic-derived therapeutics to address health problems like alcohol use disorder. Shares of Clearmind are listed on Nasdaq and Frankfurt Stock Exchange. For more information, visit their website.

Read more at GlobeNewswire: Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv